The timing of expression of blood coagulation abnormality in patients treated with warfarin and S-1 concomitantly

Takaaki Yamada, Hiroyuki Watanabe, Takahisa Yano, Toshiharu Nonaka, Atsushi Takada, Masanobu Sonoda, Toshio Kubota, Nobuaki Egashira, Ryozo Oishi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although S-1 is frequently used in cancer chemotherapy, the drug interaction with warfarin, an anticoagulant agent, is not fully paid attention. In the present study, we investigated retrospectively the timing of expression of blood coagulation abnormality in nine patients treated with warfarin and S-1 concomitantly. In five patients, the dose of warfarin was reduced or interrupted after concomitant use of S-1. The International Normalized Ratio (INR) was significantly increased after combination with S-1 compared with the former value. In all patients, the INR was increased in three weeks after combination with S-1. On the other hand, serum creatinine, aspartate aminotransferase, alanine aminotransferase or serum albumin was not different before and after combination with S-1. These results suggest that the careful monitoring of the blood coagulation ability is necessary in all patients receiving warfarin and S-1 concomitantly.

Original languageEnglish
Pages (from-to)955-960
Number of pages6
JournalYakugaku Zasshi
Volume130
Issue number7
DOIs
Publication statusPublished - Jul 1 2010

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'The timing of expression of blood coagulation abnormality in patients treated with warfarin and S-1 concomitantly'. Together they form a unique fingerprint.

Cite this